Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
Colorcon
McKinsey
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMPAVIDO

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Impavido

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01122771 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed International Centre for Diarrhoeal Disease Research, Bangladesh Phase 3 2010-05-01 This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.
NCT01122771 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed Shaheed Surhawardy Medical College and Hospital Phase 3 2010-05-01 This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.
NCT01122771 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed Drugs for Neglected Diseases Phase 3 2010-05-01 This protocol will evaluate the efficacy and safety of various combinations of the three drugs; AmBisome, Paromomycin and Miltefosine at reduced total dosage against the standard treatment with a total dose of 15mg/kg of AmBisome.
NCT01377974 Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis Completed Brasilia University Hospital Phase 2 2009-07-01 The purpose of this study is to determine whether miltefosine is effective in the treatment of mucosal leishmaniasis compared to meglumine antimoniate, the standard treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Impavido

Condition Name

Condition Name for Impavido
Intervention Trials
Visceral Leishmaniasis 3
Leishmaniasis 2
Mucocutaneous Leishmaniasis 2
Leishmaniasis or Other Uses of Miltefosine 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Impavido
Intervention Trials
Leishmaniasis 10
Leishmaniasis, Visceral 4
Leishmaniasis, Mucocutaneous 3
Leishmaniasis, Cutaneous 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Impavido

Trials by Country

Trials by Country for Impavido
Location Trials
Sudan 2
Ethiopia 2
Kenya 2
Brazil 1
Uganda 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Impavido

Clinical Trial Phase

Clinical Trial Phase for Impavido
Clinical Trial Phase Trials
Phase 3 3
Phase 2 3
N/A 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Impavido
Clinical Trial Phase Trials
Not yet recruiting 6
Completed 2
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Impavido

Sponsor Name

Sponsor Name for Impavido
Sponsor Trials
Drugs for Neglected Diseases 5
Knight Therapeutics (USA) Inc 4
University of Gondar 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Impavido
Sponsor Trials
Other 19
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Medtronic
Express Scripts
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.